Broadfin trimmed its second-largest holding, in Flamel Technologies S.A. (ADR) (NASDAQ:FLML), by 8% during the first quarter to lower the total stake to 4.72 million shares valued at $24.87 million. The holding represents more than 12% of the company’s outstanding shares and about 7% of the fund’s portfolio value. So far this year, Flamel Technologies S.A. (ADR) (NASDAQ:FLML)’s stock has posted solid gains of 13.25%. However, this performance is overshadowed by the biotechnology industry’s rise of over 17% during the same period. The $780 million pharmaceutical company’s products include Bloxiverz and Coreg CR. The former is an injection used in the operating room to reverse the effects of non-depolarizing neuromuscular blocking agents after surgery, while the latter is used for treating high blood pressure or certain types of heart failure. After Broadfin, the two largest stockholders of Flamel Technologies S.A. (ADR) (NASDAQ:FLML) within our database are James E. Flynn‘s healthcare-focused fund Deerfield Management and Israel Englander‘s Millennium Management, with respective stakes of 4.07 million shares valued at $73.23 million and 1.83 million shares valued at $32.94 million.
During the first quarter Broadfin slightly cut its stake in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) by 1% to 2.5 million shares valued at $65.49 million. The holding represents 8.76% of the company’s outstanding stock and 5.1% of the fund’s portfolio value. The stock of the $554.58 million biopharmaceutical company, which is engaged in developing treatments for patients with debilitating rare diseases, has fallen by 7.5% so far this year. In its financial results for the first quarter, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) beat both the top and bottom line estimates. However, there is a considerable amount of uncertainty surrounding the company’s future prospects. It only has one main product, Juxtapid and there is a need for diversification as competition for that drug brews up. Matt Sirovich and Jeremy Mindich’s Scopia Capital is the largest stockholder of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) within our database, owning some 5.35 million shares valued at $140.01 million.